Desert Highlands Regenerative (DHR), a private equity group in Salt Lake City, has acquired a majority ownership of Apex Biologix, a Murray-based regenerative medical company. Apex designs and manufactures XCELL platelet-rich plasma.
Apex also appointed Jeff Frey to its senior management team as chief commercial officer. Frey’s orthopedic and regenerative medicine experience spans 25 years with companies such as Johnson & Johnson Orthopedics, Integra Lifesciences and Ortho Solutions.
Apex Biologix will continue to operate under the same name; maintain its core leadership team led by its president, Troy Openshaw; and focus on the expansion of its product line and services through the commercial leadership and capital now in place, the company said.
“We have handpicked Apex Biologix to be the vehicle to grow and expand our existing footprint in the regenerative medicine market,” said Frey, who is also a partner at Desert Highlands Regenerative. “APEX Biologix has set the foundation with superior products evidenced by proven results. We are bullish about the future by providing the best products in regenerative medicine for our physicians and their patients.”
The investment in Apec aligns with DHR’s strategy to provide physicians with specialized training, comprehensive business services and premier supplies to improve their practices and enhance the lives of the patients they treat, the company said. The purchase furthers the company’s goal of becoming the leader in regenerative medicine products, it said.
“The integration of APEX Biologix and Desert Highlands Regenerative will leverage additional capital resources and distribution assets to dramatically expand Apex’s audience and reach into new markets that we’ve not serviced before. Our physicians will continue to receive the same level of high-quality products and services they have come to expect from Apex Biologix,” said Openshaw.
Established in 2014, Apex serves all 50 states and multiple countries globally, with over 2,000 active physician clients.
